These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 33717228)

  • 1. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
    Tanzawa S; Ushijima S; Shibata K; Shibayama T; Bessho A; Kaira K; Misumi T; Shiraishi K; Matsutani N; Tanaka H; Inaba M; Haruyama T; Nakamura J; Kishikawa T; Nakashima M; Iwasa K; Fujiwara K; Kohyama T; Kuyama S; Miyazawa N; Nakamura T; Miyawaki H; Ishida H; Oda N; Ishikawa N; Morinaga R; Kusaka K; Fujimoto N; Yokoyama T; Gemba K; Tsuda T; Nakagawa H; Ono H; Shimizu T; Nakamura M; Kusumoto S; Hayashi R; Shirasaki H; Ochi N; Aoe K; Kanaji N; Kashiwabara K; Inoue H; Seki N
    Ther Adv Med Oncol; 2021; 13():1758835921998588. PubMed ID: 33717228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
    Tanzawa S; Makiguchi T; Tasaka S; Inaba M; Ochiai R; Nakamura J; Inoue K; Kishikawa T; Nakashima M; Fujiwara K; Kohyama T; Ishida H; Kuyama S; Miyazawa N; Nakamura T; Miyawaki H; Oda N; Ishikawa N; Morinaga R; Kusaka K; Miyamoto Y; Yokoyama T; Matsumoto C; Tsuda T; Ushijima S; Shibata K; Shibayama T; Bessho A; Kaira K; Misumi T; Shiraishi K; Matsutani N; Seki N
    Ther Adv Med Oncol; 2022; 14():17588359221116603. PubMed ID: 35923924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
    Tanaka H; Tanzawa S; Misumi T; Makiguchi T; Inaba M; Honda T; Nakamura J; Inoue K; Kishikawa T; Nakashima M; Fujiwara K; Kohyama T; Ishida H; Kuyama S; Miyazawa N; Nakamura T; Miyawaki H; Oda N; Ishikawa N; Morinaga R; Kusaka K; Fujimoto N; Fukuda Y; Yasugi M; Tsuda T; Ushijima S; Shibata K; Shibayama T; Bessho A; Kaira K; Shiraishi K; Matsutani N; Seki N
    Ther Adv Med Oncol; 2022; 14():17588359221142786. PubMed ID: 36570411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
    BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
    JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
    Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
    Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
    Yamada T; Goto Y; Tanaka H; Kimura H; Minato K; Gyotoku H; Honda T; Watanabe S; Morimoto K; Kiyomi F; Uchino J; Takayama K
    Eur J Cancer; 2023 Dec; 195():113373. PubMed ID: 37890349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Yang Z; Zhong W; Luo Y; Wu C
    BMC Cancer; 2023 Oct; 23(1):962. PubMed ID: 37817073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A.
    Mouri A; Kisohara A; Morita R; Ko R; Nakagawa T; Makiguchi T; Isobe K; Ishikawa N; Kondo T; Akiyama M; Bessho A; Honda R; Yoshimura K; Kagamu H; Kato S; Kobayashi K; Kaira K; Maemondo M
    ESMO Open; 2024 Oct; 9(10):103939. PubMed ID: 39395258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
    Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
    Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
    Ichinose Y; Seto T; Sasaki T; Yamanaka T; Okamoto I; Takeda K; Tanaka M; Katakami N; Sawa T; Kudoh S; Saka H; Nishimura Y; Nakagawa K; Fukuoka M
    J Thorac Oncol; 2011 Dec; 6(12):2069-75. PubMed ID: 22052226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Jung HA; Noh JM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Pyo H; Ahn YC; Park K
    Lung Cancer; 2020 Aug; 146():23-29. PubMed ID: 32505077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).
    Yamada T; Uchino J; Chihara Y; Shimamoto T; Iwasaku M; Tamiya N; Kaneko Y; Kiyomi F; Takayama K
    Ther Adv Med Oncol; 2020; 12():1758835920927841. PubMed ID: 32536981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
    Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
    Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
    J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy.
    Zhou Q; Chen M; Wu G; Chang JH; Jiang O; Cui JW; Han G; Lin Q; Fang J; Chen GY; Wu YL
    Transl Lung Cancer Res; 2020 Oct; 9(5):2008-2015. PubMed ID: 33209620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
    Shimokawa T; Yamada K; Tanaka H; Kubota K; Takiguchi Y; Kishi K; Saito H; Hosomi Y; Kato T; Harada D; Otani S; Kasai T; Nakamura Y; Misumi T; Yamanaka T; Okamoto H
    Cancer Med; 2021 Jan; 10(2):626-633. PubMed ID: 33319495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
    Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
    Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer.
    Driesen P; Lambrechts M; Kraaij K; Soldatenkova V; Chouaki N; Colinet B
    Ther Adv Med Oncol; 2013 May; 5(3):159-68. PubMed ID: 23634194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.
    Hughes BG; Ahern E; Lehman M; Pratt G; Dauth M; Pritchard W; Wockner L; Horwood K
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):137-144. PubMed ID: 28181415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.